interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Apomorphine Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Apomorphine Hydrochloride, and who makes it?

Apomorphine Hydrochloride appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 1 generic maker listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 17.8 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Apomorphine Hydrochloride3 dosage-form groups in the Orange Book
1generic maker listed
  1. Apomorphine Hydrochloride appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 1 generic maker listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 17.8 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Film, Sublingual

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Injectable, Subcutaneous

One to three generic makers listed

Brand listed as marketed: Apokyn. 1 generic maker with 1 generic product listed as marketed; the first generic approval is dated 23 February 2022.

200020052010201520202025203001brand 2004Tp Anda Holdings Llc, first approval 23 February 2022data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Tp Anda Holdings Llc23 February 20221

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Onapgo. No generic is listed as marketed.

20202025203001brand 2025data dateExclusivity NP to 3 February 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 3 February 2028Exclusivity NP Onapgo

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.